Business Wire

ERBE-ELEKTROMEDIZIN

6.6.2024 08:12:27 CEST | Business Wire | Press release

Share
Erbe Elektromedizin inaugurates new competence center for medical instruments in Rangendingen, Germany, and expands its capacities for customers all over the world

Erbe Elektromedizin has inaugurated a new production and development building in Rangendingen, Germany, after three years of construction. At 90 million euros, the new 25,000 m² building is the largest single investment in the company's history and represents another important part in the global network. The building combines production, product development, logistics and administration. Erbe will now develop and produce medical technology instruments for customers all over the world at its Rangendingen site near Tübingen. With the new building, the company is expanding its capacities and is even better equipped to deal with the consequences of global crises. The building is a pioneering achievement in terms of ecological, social and economic sustainability. Among the guests on May 3 were the Chairman of the Free Democratic Party, Christian Lindner, and the Minister of Economic Affairs of Baden-Württemberg, Dr. Nicole Hoffmeister-Kraut.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240603323747/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

New Erbe production and development building in Rangendingen, Germany (Photo: Business Wire)

On May 3rd, Erbe opened its newest plant in Rangendingen near Tübingen. The new competence center is dedicated to the development and production of medical instruments for our customers around the world. Erbe is expanding its capacities in order to be even more robust in case of supply bottlenecks resulting from international crisis. In this manner, Erbe ensures uninterrupted business operations. This enables us to consistently deliver the highest quality to our customers worldwide.

An important aspect for ensuring continuous economic success is the concept of sustainability. For Erbe, “Made in Germany” means the future of Germany as a business location in harmony with innovative medical technology and a pioneering role for sustainable, responsible entrepreneurship.

“Erbe is a symbol of what makes our country strong,” explained Christian Lindner, Chairman of the Free Democratic Party (FDP) in his speech. He commended the location decision and emphasized the importance of supporting family businesses, stating, “They are the ones who create prosperity.”

“We have set the course for a new standard with our construction project in Rangendingen,” explains Marcus Felstead, Chief Commercial Officer.

“Because tomorrow's customers will place even more value on sustainability than we already do today. We want to meet these demands.”

Both planning and construction of the building had this as a goal. In order to realize ecological, social and economic aspects of the corporate strategy and combine them in an industrial building, Erbe relied on the use of high-quality ecological building materials for the supporting structure and the façade, the use of renewable energy technology and the implementation of numerous measures for an optimal working environment for employees.

A highlight of the building is one of the largest photovoltaic systems in the region. The 2,800 solar panels on the roof with an output of 1 MW produce 610,000 kWh of electricity per year and cover a third of the energy required for operations. This is supplemented by a combined heat and power plant powered by CO2-neutral biogas.

“We implemented the most demanding standards for energy efficiency and achieved KfW Efficiency Level 40 Plus,” explains Christian O. Erbe. “This means, that our building is more than twice as energy efficient compared to conventional structures, making it a leader in the field of sustainable industrial building.”

Up to 500 employees will be working on site. They benefit from a modern, employee-centered working environment. The company's social responsibility also includes a distinctive health concept for employees, including company medical care, health weeks and financial support for sporting activities. There are exercise islands in the building for fitness, a room for yoga, leisure activities and relaxation rooms.

About Erbe Elektromedizin

Erbe Elektromedizin develops, manufactures, and distributes surgical instruments and devices worldwide, while providing services for professional use of these products in a diverse range of medical disciplines. Surgeons, OP teams and patients around the world rely on Erbe medical technology. The surgical instruments and devices find use in almost all specialist areas. They are based on electrosurgery combined with other Erbe technologies. Hybrid solutions enable us to provide new, innovative applications in medicine.

Fields of activity

  • Imaging
  • Endoscopy
  • Electrosurgery
  • Plasma surgery
  • Thermofusion
  • Hydrosurgery
  • Cryosurgery

An international network

  • 18 international sales and service units
  • 4 production sites
  • Erbe is active in 110 international markets.

The Erbe workforce

  • Over 1,900 employees worldwide
  • Some 1,000 of them in Germany

Erbe Elektromedizin GmbH
Waldhoernlestr. 17,
72072 Tübingen
www.erbe-med.com
info@erbe-med.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240603323747/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Unleashing GEN4: a New Era of High-performance, Sustainable Electric Racing Begins21.4.2026 17:54:00 CEST | Press release

The debut of the GEN4 race car underlines a step change in electric racing performance. Set for its competitive debut in the 2026/27 Season, the GEN4 machine has a 71% increase in power. More road-relevant than ever, many of the biggest OEMs will take these innovations from track to road. The Fédération Internationale de l'Automobile (FIA) and Formula E have unleashed the GEN4 car on track in its debut run in the South of France, signalling the beginning of a new era for electric motor sport. This all-new car will be raced in the 2026/27 Season of the ABB FIA Formula E World Championship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421618886/en/ Unleashing GEN4: A new era of high-performance, sustainable electric racing begins Capable of speeds over 335kph (208mph), 0-100kph in approximately 1.8s, and 0-200kph in just 4.4s - 1.5s faster than its predecessor. GEN4 produces up to 600kW of power, a 71% increase in base ou

Resale on the Rise: Klarna's Resell Feature Grows 75% as Consumers Put Real Money Back in Their Pockets21.4.2026 17:00:00 CEST | Press release

New data from Klarna reveals consumers are making an estimated $137 per sold item as resale becomes a go-to financial habit New data from Klarna,the global digital bank and flexible payments provider, reveals that its in-app resell feature is gaining significant momentum:listings created through the app grew by up to 75% over the past 13 months*, as consumers increasingly turn to resale as a way to earn real money from items they already own. The data points to a broader shift in financial behaviour: consumers are increasingly treating the things they own not as fixed costs, but as assets with ongoing value. Reselling is becoming routine, not a one-off First launched in Sweden in 2022, Klarna's resell feature is now available across 15 markets, letting users list items for resale directly from their purchase history via leading resale marketplaces such as eBay, Poshmark and Tradera. No need to remember what they paid, find the receipt, or switch to another app. Klarna pre-fills key lis

Frasca Pilatus PC-12 PRO Flight Training Device Receives FOCA Qualification21.4.2026 16:05:00 CEST | Press release

Training device developed for the Pilatus PC-12 PRO with Garmin’s G3000 PRIME Integrated Flight Deck Frasca International, Inc., a FlightSafety International company and global leader in flight simulation, today announced that its Pilatus PC-12 PRO Flight Simulation Training Device (FSTD) received Level 2 Flight Training Device (FTD2) and Flight and Navigation Procedures Trainer (FNPT II) qualification from Switzerland’s Federal Office of Civil Aviation (FOCA). Frasca is the first to develop a PC-12 PRO training device. The device equipped with Garmin’s G3000 PRIME Avionics suite is installed at Pilatus Aircraft Ltd headquarters in Stans, Switzerland, where it will support training for the next generation of PC-12 pilots. The qualification enables pilots to complete a wide range of instruments, procedural and advanced systems training in a highly immersive environment that mirrors the capabilities of the aircraft. “The PC-12 PRO leads the way with advanced features, and we’re proud to

Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting21.4.2026 16:00:00 CEST | Press release

- Data from pivotal frontMIND study of tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) featured in oral presentation at ASCO; results support global regulatory submissions Incyte (Nasdaq:INCY) today announced that full results from the Phase 3 pivotal study evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) will be featured as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago. “The positive Phase 3 frontMIND results for tafasitamab in patients with newly diagnosed diffuse large B-cell lymphoma highlight Incyte’s continued focus on advancing novel differentiated approaches with the potential to meaningfully impact patients,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “We look forward to sharing the full data at ASCO, and to progressing our pipeline.” Presentation details:

Wolters Kluwer CCH Tagetik Kicks Off Global inTouch 2026 Series Showcasing Expert AI in Action for the Office of CFO21.4.2026 15:28:00 CEST | Press release

Wolters Kluwer CCH Tagetik is set to host Global inTouch 2026, its flagship user conference which takes place May 19–21, 2026, in Lucca, Italy. Celebrating its 20th edition, Global inTouch launches a global event series demonstrating how CCH Tagetik with Expert AI is transforming the way finance works with AI-enabled capabilities embedded directly into the processes that matter most to the office of the CFO. Following the event in Lucca, the Global inTouch showcase will continue with regional inTouch events across key markets worldwide, including Belgium, France, Germany, Japan, the Netherlands, Sweden, the United Kingdom, and the United States. This year’s theme, Own the Future, reflects Wolters Kluwer CCH Tagetik’s commitment to continuous innovation and to empowering finance teams to deliver impact today while confidently shaping what’s next. “The role of the CFO is expanding from reporting on the past to strategically orchestrating the future to maximize value creation,” saidMaria

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye